title: The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients.
abstract: OBJECTIVE
  The role of angiogenesis has been extensively evaluated in solid tumors and more recently in hematologic malignancies. Several surrogate markers of angiogenesis including tumor VEGF, VEGF receptors, and microvessel density have correlated with outcome in some lymphoma studies. This is a single institution retrospective study evaluating the role of angiogenesis markers in the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL).
  
  
  METHODS
  A total of 97 patients with DLBCL diagnosed and managed at Indiana University between 1993 and 2001 were included. Archived tumor samples were stained for VEGF-A, VEGF-C, VEGF-R1, and CD31 and graded as negative or positive (1+, 2+, 3+). The relationship between the expression of these markers and the international prognostic variables as well as the progression free survival (PFS) and the overall survival (OS) was evaluated.
  
  
  RESULTS
  VEGF-A, VEGF-C, VEGF-R1 were expressed in 77, 98, and 18% of tumors, respectively. VEGF-A negative patients had an improved OS compared to VEGF-A (1+) (P = 0.0502). VEGF-C correlated with both LDH (r = 0.28, P = 0.0502) and IPI score (r = 0.25, P = 0.013). VEGF-R1 negative patients had a superior survival compared to those with VEGF-R1 (2+) (P = 0.0154).
  
  
  CONCLUSIONS
  The presence of tumor associated angiogenesis may alter the outcome of patients with DLBCL and could be a prognostic factor. Further clinical studies are needed to correlate the degree of angiogenesis with response to anti-angiogenesis agents.
authors: Division of Oncology, Stanford University, Stanford, CA, USA. kganjoo@stanford.edu
authors: Kristen N
authors: KN
authors: Ganjoo
authors: Annette M
authors: AM
authors: Moore
authors: Attilio
authors: A
authors: Orazi
authors: Joy A
authors: JA
authors: Sen
authors: Cynthia S
authors: CS
authors: Johnson
authors: Caroline S
authors: CS
authors: An
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000378:metabolism; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D011379:Prognosis; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis / Q000378:metabolism; D042582:Vascular Endothelial Growth Factor C / Q000032:analysis / Q000378:metabolism; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000032:analysis / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D042582:Vascular Endothelial Growth Factor C; D040281:Vascular Endothelial Growth Factor Receptor-1
references: Leuk Lymphoma. 2003 Dec;44(12):2089-93
references: 14959852
references: Eur J Haematol. 2004 Nov;73(5):311-7
references: 15458509
references: Breast Cancer Res Treat. 1995;36(2):169-80
references: 8534865
references: Blood. 2004 Nov 1;104(9):2893-902
references: 15238424
references: Cell Tissue Res. 2003 Oct;314(1):167-77
references: 12883995
references: Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11709-14
references: 9751730
references: Lancet Oncol. 2006 May;7(5):379-91
references: 16648042
references: Leuk Lymphoma. 2009 May;50(5):728-35
references: 19373598
references: Acta Medica (Hradec Kralove). 2005;48(1):57-8
references: 16080387
references: Cancer Res. 1997 Oct 15;57(20):4593-9
references: 9377574
references: Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14389-94
references: 9826710
references: Leuk Lymphoma. 2006 Jun;47(6):998-1005
references: 16840188
references: Science. 1992 Feb 21;255(5047):989-91
references: 1312256
references: Folia Histochem Cytobiol. 2006;44(1):43-7
references: 16584091
references: Nature. 2000 Feb 3;403(6769):503-11
references: 10676951
references: N Engl J Med. 2006 Dec 14;355(24):2542-50
references: 17167137
references: N Engl J Med. 2004 Jun 3;350(23):2335-42
references: 15175435
references: Med Oncol. 2000 Nov;17(4):314-8
references: 11114711
references: Int J Cancer. 2000 Jan 15;85(2):171-5
references: 10629073
references: Blood. 2001 Sep 15;98(6):1904-13
references: 11535528
references: J Biol Chem. 1994 Oct 14;269(41):25646-54
references: 7929268
references: J Clin Oncol. 2006 Jul 1;24(19):3121-7
references: 16754935
references: N Engl J Med. 1992 Nov 5;327(19):1342-9
references: 1383819
references: Ann Hematol. 2005 Aug;84(8):510-6
references: 15834569
references: N Engl J Med. 2002 Jan 24;346(4):235-42
references: 11807147
references: Endocr Rev. 2004 Aug;25(4):581-611
references: 15294883
references: Br J Haematol. 2005 Sep;130(6):869-77
references: 16156857
references: Science. 1997 May 30;276(5317):1423-5
references: 9162011
references: Am J Pathol. 1997 Mar;150(3):815-21
references: 9060819
references: N Engl J Med. 1999 Nov 18;341(21):1565-71
references: 10564685
references: N Engl J Med. 1993 Apr 8;328(14):1002-6
references: 7680764
references: Blood. 2000 Dec 1;96(12):3712-8
references: 11090051
references: N Engl J Med. 1993 Sep 30;329(14):987-94
references: 8141877
references: Neoplasma. 2005;52(2):175-81
references: 15800717